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The American Cancer Society has estimated
that more than 182,800 new cases of breast
cancer will be diagnosed in American women
in the year 2000, and one in four of these
women (40,800) will die of this disease (1).
Because only about half of breast cancer risk
can be attributed to established risk factors,
including sex, advancing age, early menarche,
late menopause, late age at first birth, and
first-degree relative with breast cancer (2,3),
there has been continued interest in the role
environmental contaminants may play in
unexplained breast cancer risk (4,5). Ovarian
hormones, including estrogen and proges-
terone, may affect breast cancer risk by affect-
ing rates of cell proliferation in the breast or
by supporting the growth of estrogen-
dependent breast tumors (6–10). Hormonally
active agents found in the environment that
affect breast cell proliferation by acting as
estrogen mimics or by disrupting pathways
leading to enhanced breast cell proliferation
may also affect breast cancer risk. In this
review I discuss the results of human epi-
demiologic studies that have evaluated
whether the persistent organochlorine insecti-
cides dichlorodiphenyltrichloroethane
(DDT) and dieldrin affect the incidence or
mortality of breast cancer.
DDT and DDE
Over the last decade numerous epidemiologic
investigations have been conducted to investi-
gate whether environmentally persistent
organochlorine pesticides affect the risk of
breast cancer. The most widely studied pesti-
cide has been DDT, an insecticide ﬁrst used
during World War II for control of lice and
mosquitoes to combat typhus and malaria,
respectively (11). DDT was used extensively
in the United States for insect control in
forestry and agriculture and for vector con-
trol until it was banned by the U.S.
Environmental Protection Agency (U.S.
EPA) in 1972 (12). Production of DDT
reached its peak during the early 1960s at 81
million kg/yr (13). By 1966, although pro-
duction had decreased, agricultural applica-
tions accounted for about 38% of the DDT
used in the United States (14). By the early
1970s, use of DDT in the United States had
declined dramatically to 4.5–6.4 million
kg/yr, and its primary use was for pest con-
trol on cotton crops (14). However, agricul-
tural regions were not the only areas with
potential DDT contamination. It has been
estimated that 2 million kg of DDT was
expelled into the Los Angeles sewer system
between 1949 and 1970 (15). Reproductive
malformations in birds, including the femi-
nization of male Channel Island gulls off the
coast of southern California, have been
attributed to DDT contamination (15–18).
Forested areas were also sprayed extensively
with DDT. During the 1980s and 1990s
many Third World countries banned the use
of DDT in agriculture, but use for vector
control is still allowed. India banned the use
of DDT in agriculture in 1989, although use
against malaria-bearing mosquitoes is still
prevalent (19).
The most prevalent breakdown product of
DDT—dichlorodiphenyldichloroethylene
(DDE)—persists in the environment, concen-
trates up the food chain (20), is stored in fatty
tissues of animals, ﬁsh, and humans (21–29),
is widely detected in breast milk (30–34) and
cows’ milk (35–37), and has been detected in
household dust and air (38,39).
Why Evaluate DDT/DDE 
and Breast Cancer Risk?
Several lines of evidence supported investigating
whether DDT or its metabolites affected
breast cancer risk. These include the identiﬁ-
cation of some congeners of DDT as environ-
mental estrogens (40–48). Technical DDT
and o,p´-DDT, the most estrogenic compo-
nent of technical DDT, can support the
growth of estrogen-dependent breast tumors
in rats, whereas metabolites of DDT that do
not bind to the estrogen receptor (ER), such
as dichlorodiphenyldichloroethane (p,p´-
DDD), are unable to support breast tumor
growth (49). There is limited evidence that
DDT may act as a promoter of mammary
tumors in rats (50) and can inhibit gap junc-
tional intercellular communication (51).
Other evidence of hormone-disrupting effects
of DDT and its metabolites has included
reproductive defects and eggshell thinning in
avian species (16–18), sex reversal in medaka
ﬁsh (52), and changes in sexual differentiation
and behavior in mice (53). The persistent
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Table 1. Human epidemiologic studies on DDE and breast cancer risk.
First author (ref.) Year(s) collected  Type of DDE concentration, mean (SD)
Place (year published) sample  Cases/controls  control Cases Controls (units) OR (95% CI)a p Trend Association
Nested case–control studies, serum
Krieger (63)
California (1994) 1964–1971 150/150 43.3 (25.9) 43.1 (23.7) ppb 1.33 (0.68–2.2) p = 0.43 None
White 1964–1971 50/50 35.7 (23.0) 35.0 (22.8) ppb 2.38 (0.54–10.64) p = 0.238 None
Black 1964–1971 50/50 49.2 (28.6) 43.4 (21.2) ppb 3.85 (0.93–16.05) p = 0.066 None
Asian 1964–1971 50/50 45.1 (24.5) 50.8 (24.7) ppb 0.71 (0.23–2.18) p = 0.516 None
Helzlsouer (73) 1974 346/346 11.5 (7.1) 13.6 (10.6) ng/mL 0.5 (0.27–0.89) p = 0.02 Negative
Maryland (1999) 1989 7.9 (6.4) 9.7 (3.6) ng/mL 0.53 (0.24–1.17) p = 0.08 None
(volume basis)
1974 346/346 1,699 (929)b 1,920 (1,409) ng/gb 0.73 (0.40–1.32)  p = 0.13 None
1989 1,311 (1,037)b 1,586 (1,557) ng/gb 0.58 (0.29–1.17) p = 0.15 None
(lipid basis)
Høyer (74) 1976 240/477 Not provided 0.88 (0.56–1.37) p = 0.52 None
Denmark (1998)
Dorgan (75) 1977–1987 105/208 NA 16.3 ng/mL 0.8 (0.4–1.5) p = 0.77 None
Missouri (1999) (median)
Wolff (77) 1985–1991 58/171 11.8 (9.1) 7.7 (6.8) ng/mL 3.68 (1.01–13.50) p = 0.035 Positive
New York (1993)
Wolff (64) 1987–1992 148/295 6.95 (2.46) 7.27 (2.39) ng/mL
New York (2000) 110/213 977 (2.46)b 1,097 (2.29) ng/gb 1.30 (0.51–3.35) p = 0.99 None
ER negative status 32/64 8.56 (1.87) 6.42 (2.36) ng/mL
ER positive status 57/111 7.04 (2.51) 7.26 (2.21) ng/mL
ER negative status 23/42 1,300 (1.79)b 1,040 (2.14) ng/gb
ER positive status 44/83 950 (2.41)b 1,040 (2.16) ng/gb
Hunter (76) 1989–1990 236/236 6.01 (4.56)c 6.97 (5.99) ppbc 0.72 (0.37–1.40) p = 0.47 None
Massachusetts (1997) 
Case–control studies, serum
Moysich (78)
New York State (1998) 1986–1991 154/192 CC 11.47 (10.49)b 10.77 (10.64) ng/gb 1.34 (0.71–2.55) p = 0.25 None
Never lactated 46/61 13.15 (11.65)b 10.82 (10.91) ng/gb 1.83 (0.63–5.33) p = 0.24 None
Ever lactated 85/106 10.36 (8.97)b 10.44 (10.43) ng/gb 1.28 (0.54–3.05) p = 0.44 None
Romieu (90) 1990–1995 120/126 CC 3.84 (5.98)b 2.52 (1.97) µg/gb 3.81 (1.14–12.80) p = 0.02 Positive
Mexico (2000) (lipid basis)
24.2 17.5 µg/L
(wet weight basis)
Schecter (79)
North Vietnam (1997)  1994 20/20 BBD 12.17 (2.41) 16.67 (4.14) ng/mL 1.14 (0.23–5.68) None
Lopez-Carrillo (80)
Mexico (1997) 1994–1996 141/141 HC 562.5 (676.2)b 505.5 (567.2) ppbb 0.76 (0.41–1.42) None
(lipid basis)
4.75 (5.04) 4.07 (4.12) ppb Not provided None
(wet weight basis)
Demers (81) 1994–1997 314/218 HC 508.9 (491.1)b 462.7 (447.7) µg/kgb 1.36 (0.71–2.63) None
Quebec, Canada (2000) 314/305 CC 480.4 (408.1) µg/kgb 1.00 (0.60–1.67) None
Olaya-Contreras (82)  1995–1996 153/153 HC 3.30 (4.12) 2.50 (3.60) ng/mL 1.95 (1.10–3.52) p = 0.09 None
Colombia, So. Am. (1998)
Mendonca (83) 1995–1996 151/306 CC 3.1 4.8  ng/mL 0.83  (0.40–1.6) p = 0.79 None
Brazil (1999)
Zheng (84) 1995–1997 475/502 BBD 460.1b 456.2 ppbb 0.96 (0.67–1.36) p = 0.58 None
Connecticut (2000)
Cases, ER negative status 163/ 435.1 ppbb Not reported
Cases, ER positive status 140/ 435.9 ppbb Not reported
Dello Iacovo (85) 1997–1998 170/195 CC 9.55 (5.42) 8.98 (5.17) ng/mL None
Italy (1999)
Descriptive and case–control studies, adipose tissue
Unger (69) Early 1980s 14/21 HC 1.23 (0.63) 1.25 (0.76) ppm None
Denmark (1984) (surgery for noncancer breast diseases)
Falck (72) 1987 20/20 BBD 2,200 (1,470) 1,487 (842) ng/gb Positive
Connecticut (1992) t-test, p = 0.07
(Continued)
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metabolite p,p´-DDE and to a lesser extent
the DDT isomer p,p´-DDT are still detected
in low amounts in food, especially in fish,
meat and dairy products, and root vegetables
(26,35,54–59). DDT and DDE are stored in
human adipose tissue, and levels increase as a
function of age (21,60,61). However, the lev-
els of DDE detected in food (26,62) and in
blood and adipose tissues of humans in
Western countries (21,62–65) have been
decreasing since the decline of DDT use dur-
ing the 1960s. Even though DDT sales and
use were banned in the United States and
Canada in the early 1970s, new deposits of
DDT are still detected in North America
through aerial deposition from other countries
that continue to use DDT (66). The continu-
ation of new inputs via atmospheric deposi-
tion in the Arctic Circle is supported by the
relatively high body burdens of DDE reported
in native populations of Greenland (67).
Overview of the Epidemiologic Studies
on DDT, DDE, and Breast Cancer Risk
One of the ﬁrst studies that explored a possi-
ble relationship between tissue levels of DDE
and cancer risk in women was conducted by
Unger and Olsen (68). Levels of DDE in adi-
pose tissue increased as a function of age in
both men and women with and without
cancer. Mean levels of DDE extracted from
abdominal adipose tissue were higher in a
group of 11 women with cancer [5.03 parts
per million (ppm)] compared to 22 women
without cancer (2.14 ppm). In a small follow-
up study, breast adipose tissue biopsy samples
were obtained from 14 women with breast
cancer and 21 women with other noncancer-
ous breast diseases (69). There was no rela-
tionship between mean levels of DDE in
women with breast cancer (1.23 ppm) com-
pared to those in controls (1.25 ppm). Several
other small case–control studies conducted in
the early 1990s compared adipose tissue levels
of DDE in women with breast cancer to con-
trols without breast cancer (70–72). These
studies found a positive relationship between
DDE levels and breast cancer risk (Table 1);
however, interpreting the signiﬁcance of these
results and the studies by Unger et al. is difﬁ-
cult because of their very small sample size
(< 25 cases), use of controls with benign or
other types of breast disease, and lack of con-
trol for potential confounding factors that
could affect breast cancer risk. 
These early descriptive and case–control
studies stimulated interest in investigating the
relationship between DDT and DDE and
breast cancer risk, and led to more carefully
designed nested case–control studies (63,64,
73–77) and case–control studies (78–92) that
are summarized in Table 1. These studies
considered the effects of various confounding
factors on the relationship between tissue
DDE levels and breast cancer risk. Mussalo-
Rauhamaa et al. (91) compared adipose tis-
sue levels of p,p´-DDT and p,p´-DDE from
44 women with breast cancer to levels in
postmortem tissue samples from 33 women
who had died accidental deaths. There were
no significant differences between cases and
controls for any of the potential confounders,
including age, residential history, lactation,
body weight, height, parity, smoking history,
or diet (fish consumption). There were no
differences between mean levels of DDE or
DDT between cases (p,p´-DDT 0.07 ± 0.09
mg/kg fat; p,p´-DDE 0.96 ± 0.63 mg/kg fat)
and controls (p,p´-DDT 0.06 ± 0.07 mg/kg
fat; p,p´-DDE 0.98 ± 0.89 mg/kg fat),
respectively.
Two prospective nested case–control
studies with very different conclusions were
published in the early 1990s. Wolff et al. (77)
obtained blood samples between 1985 and
1991 from 14,290 women enrolled in the
New York University Women’s Health
Study. The cohort members who developed
breast cancer (n = 58) and controls (n = 171)
were matched for age at entry into the study,
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Mussalo-Rauhamaa (91) 1985–1986 44/33 PM 0.96 (0.63) 0.98 (0.89) mg/kg None
Finland (1990)
Dewailly (70) 1991–1992 /17 BBD 765.3 (526.9) µg/kg
Canada (1994)
Cases, ER negative 9/ 608.9 (338.9) µg/kg None
Cases, ER positive 9/ 2,132.2 (2,049.9) µg/kg Positive
Djordjevic (71) Early 1990s 5/5 HC 379 (286) 160 (149) ppb Positive
New York (1994)
Güttes (86) 1993–1994 45/20 BBD 805 496  µg/kg Positive
Germany (1998) (age adjusted, p = 0.017)
Liljegren (87) 1993–1995 35/43 BBD 767 1,026 ng/g  0.4 (0.1–1.2) Negative 
Sweden (1998)
Zheng (92)
Connecticut (1999) 1994–1997 304/186 BBD 736.5 736.5 ppb 0.9 (0.5–1.5) p = 0.46 None
van’t Veer (88) 1996 347/374 HC, CC  1.35 1.51 µg/g 0.48 (0.25–0.95) None
Europe (1997) (median)
Aronson (89)
Canada (2000) Late 1990s 217/213 BBD 693 596 µg/kg 1.62 (0.84–3.11) None
First author (ref.) Year collected Correlation between adipose tissue 
Place (year published) sample DDE and breast cancer mortality Association
Mortality correlation study, adipose tissue
Cocco (108) 1968
United States (2000)
White women –0.731**  Negative
Black women –0.501*  Negative
Abbreviations: BBD, benign breast disease controls; HC, hospital controls (hospitalized for nonbreast disease and noncancer related conditions unless otherwise noted); CC, community or population con-
trols; PM, postmortem autopsy controls; ref., reference number; SD, standard deviation; So. Am., South America. 
aOR adjusted for potential confounding factors, comparison between highest and lowest levels of DDE (i.e., tercile, quartile, or quintile). bSerum DDE adjusted for lipid concentration. cPlasma DDE adjusted
for cholesterol. 
*p < 0.05. ** p < 0.01.
Table 1. Continued.
First author (ref.) Year(s) collected  Type of DDE concentration, mean (SD)
Place (year published) sample  Cases/controls  control Cases Controls (units) OR (95% CI)a p Trend Association
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menopausal status, and dates of blood
donations. The relative risk of developing
breast cancer was nearly 4-fold higher in the
women with the highest levels of serum DDE
[odds ratio (OR) 3.68, 95% conﬁdence inter-
val (CI) 1.01–13.50, p trend = 0.035; highest
quintile was compared to lowest quintile].
Relative risks were adjusted for first-degree
family history of breast cancer, lactation, and
age at ﬁrst full-term pregnancy.
These ﬁndings were in contrast to conclu-
sions drawn from the results of a nested
case–control study conducted in northern
California (63). Subjects were from a cohort
of 57,040 women who donated blood sam-
ples from 1964 to 1971, a period when DDT
was still in use in the United States. The
mean time between obtaining the blood sam-
ples and the diagnosis of breast cancer was
14.2 years. The serum DDE levels were com-
pared in 150 breast cancer cases to 150
matched controls. There were no statistically
significant differences in the relative risk of
developing breast cancer between women in
the highest tercile for serum DDE levels com-
pared to women in the lowest tercile [OR
1.33, 95% CI 0.68–2.2; OR adjusted for
body mass index (BMI), age at menarche,
ever vs. never pregnant, menopausal status,
year of examination, and length of follow-up
time]. Nor were there significant differences
within white, Asian, or black subgroups (50
cases and controls in each subgroup),
although serum DDE levels tended to be
higher among black cases than controls
(Table 1). The signiﬁcance of the results from
the different racial/ethnic subgroups is
discussed more fully later in this review.
From 1997 to June 2000, five more
nested case–control studies were published
comparing levels of DDE in serum of women
with and without breast cancer. This includes
studies conducted in American women in
Maryland by Helzlsouer et al. (73) and in
Missouri by Dorgan et al. (75), a follow-up of
the New York University Women’s Health
Study by Wolff et al. (64), a nested case–
control study drawn from the Harvard
Nurses’ Health Study cohort by Hunter et al.
(76), and a study of Danish women enrolled
in the Copenhagen City Heart Study by
Høyer et al. (74). The results of these studies
are summarized in Table 1 in chronologic
order according to when the blood samples
were obtained. 
None of these studies supported the
findings of the 1993 study by Wolff et al.
(77) that a strong positive relationship exists
between breast cancer risk and serum DDE
levels. Wolff et al. (64), in a subsequent fol-
low-up study that included 148 breast cancer
cases and 295 matched controls, did not con-
firm their previous observation of increased
breast cancer risk with higher body burdens
of DDE. Instead they reported no association
of DDE serum levels and breast cancer risk
(OR 1.33, 95% CI 0.51–3.35, p trend =
0.99) even when the relative risk was adjusted
for potential confounders such as age at
menarche, number of full-term pregnancies,
family history of breast cancer, lactation his-
tory, height, BMI, and menopausal status.
The four other cohort studies published since
1998 reported relative risks below 1, even
after adjusting for confounders (73–76). 
Similarly, most of the well-controlled
case–control studies published since 1998
failed to ﬁnd a signiﬁcant positive relationship
between breast cancer risk and the levels of
DDE or DDT in blood (78–81,83–85) or in
adipose tissue (87–89,91,92). Although some
studies have reported relative risks > 1.1
(78,79,81,89) or < 0.9 (80,83,87), none of
these studies had ORs that reached statistical
signiﬁcance, and this supports a lack of associ-
ation. One of the few studies that has reported
a positive relationship between serum DDE
levels and breast cancer risk was conducted in
153 women with breast cancer and 153 age-
matched controls from Colombia, South
America (82). Plasma DDE levels were sig-
nificantly higher (p < 0.025) in the subjects
with breast cancer (3.30 ± 4.12 ng/mL) than
those in hospital controls without breast
cancer (2.50 ± 3.60 ng/mL). However, the
relative risks were at the borderline of statisti-
cal significance when upper and lower ter-
ciles were compared, even though the
confidence interval did not embrace 1 (OR
1.95, 95% CI 1.10–1.32, p trend = 0.09).
Use of DDT in Colombia, although lower
than in other South American countries, is
more recent than use in the United States. A
case–control study of 120 women with breast
cancer and 126 age-matched community
controls from Mexico City, Mexico, also
found a positive association between serum
p,p´-DDE levels and breast cancer risk (OR
3.81, 95% CI 1.14–12.80, p trend = 0.02),
whereas serum p,p´-DDT levels were not
related to breast cancer risk (90). As I discuss
later in this review, in contrast, other studies
conducted in countries with current or
recent DDT use have not confirmed a rela-
tionship between DDE exposure and breast
cancer risk (79,80,83). 
The only investigation that has reported a
positive relationship between tissue levels of
DDE and breast cancer risk in a Western
country was a case–control study conducted
in Germany (86). A signiﬁcantly higher (p =
0.017) mean level of p,p´-DDE was found in
the breast tumor tissue of 45 women with
breast cancer (805 µg/kg) compared to breast
tissue obtained from 20 women with benign
breast disease (BBD) (496 µg/kg). However,
interpretation of this study is difﬁcult because
instead of comparing a sample of breast tissue
adjacent to the tumor, the levels of DDE in
the tumor tissue itself were compared to
DDE levels in the breast tissue of the controls
who had BBD.
Differences in Analytic Methodologies 
There have been some discussions among
researchers of the advantages and disadvantages
of using serum versus adipose tissue levels to
determine body burdens of organochlorine
compounds, including DDE or DDT. The
half-life of DDE in humans has recently been
estimated at 13 years (64). Because of its per-
sistence and slow elimination from the body,
DDE is the most prevalent form of DDT
detected in human tissues. Adipose tissue sam-
ples have the advantage of having higher val-
ues for organochlorines than blood, and breast
adipose samples predict the level of organo-
chlorines to which the breast is exposed over
time (89). However, because obtaining adi-
pose tissue samples is highly invasive, this usu-
ally limits the availability of the control
population that can be recruited, and most of
the adipose tissue case–control studies con-
ducted have used women with BBD or
women being admitted for a breast biopsy
sample as controls. Several recent studies have
shown good agreement between adipose tissue
and blood levels of DDE (22,93,94). Hence,
there is evidence that blood levels of DDE are
a good approximation of the DDE stored in
adipose tissue. 
One study has examined the relationship
between the ratio of adipose DDE levels and
serum DDE levels. The ratio was nearest to a
value of 1 when serum DDE levels were
expressed as the geometric mean on a lipid
basis, and did not approach 1 when expressed
as the arithmetic mean or on a wet weight
basis (94). To achieve normality, serum DDE
levels are often converted to another scale
(log, square root) before statistical compar-
isons are made. However, it is desirable to
have the arithmetic means to compare results
of different studies. 
Some studies have expressed blood DDE
levels on a volume or wet weight basis (63,73,
75,77,79,80,82,83,85), whereas others have
corrected blood DDE levels for lipid
(64,73,78,80,81,84,90) or cholesterol con-
tent (76). Because DDE is carried in the lipid
fraction of the blood, expressing serum DDE
levels adjusted for lipid content is generally
considered a more desirable method for
reporting serum DDE levels. Because serum
lipid levels rise with fasting, this is an espe-
cially important correction when blood sam-
ples were obtained in a fasting state. The
units used to express serum DDE levels
affected the signiﬁcance of the results in one
study. Helzlsouer et al. (73) found a signifi-
cant negative relationship when ORs were
calculated based on serum DDE levels
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expressed on a volume basis as nanograms per
milliliter (OR 0.5, p trend = 0.02), but there
was not a statistically signiﬁcant negative rela-
tionship when ORs were calculated based on
serum DDE levels expressed per gram of lipid
(OR 0.73, p trend = 0.13) (Table 1). Lopez-
Carrillo et al. (80) and Wolff et al. (64) did
not ﬁnd an association of serum DDE levels
with breast cancer risk regardless of whether
the results were expressed on a volume or a
lipid-corrected basis. As mentioned previ-
ously, in an earlier study conducted with the
same cohort Wolff et al. (77) found a strong
positive relationship between serum DDE
levels and breast cancer risk. Although the
serum DDE levels in this study were
expressed on a per-volume basis, it is unlikely
that a correction for lipid levels would explain
the magnitude of the difference between the
mean serum DDE levels in cases (11.8 ± 9.1
µg/mL) and controls (7.7 ± 6.8 µg/mL).
Romieu et al. (90) reported a significantly
higher (p < 0.05) mean serum p,p´-DDE level
in women with breast cancer (24.2 µg/L; 3.84
µg/g lipid) compared to community controls
without breast cancer (17.5 µg/L; 2.51 µg/g
lipid) when results were expressed on a vol-
ume basis or when corrected for lipids,
respectively. A lack of an association of serum
DDE levels and breast cancer risk has been
reported both in studies that have (64,73,74,
76,78,80,81,84) and have not (63,75,79,
83,85) corrected for the lipid or cholesterol
content of serum. Therefore, there does not
appear to be a tendency to report positive
relationships between serum DDE levels and
breast cancer risk in the studies that have not
adjusted serum DDE levels for lipid content.
Differences in analytic methodology,
quality control (QC), and quality assurance
(QA) programs may affect the magnitude of
tissue DDE levels reported in different labora-
tories. It is beyond the scope of this review to
give an in-depth review of the analytic control
procedures used in each study; however, this
section provides an overview of the procedures
used by different laboratories. Most investiga-
tors reported using an analytic procedure to
determine DDE in serum/tissue that included
extracting samples with organic solvents to
obtain the lipid fraction, concentration of the
sample, purification using Florisil columns,
and identification and quantification of the
DDE in the sample by high-resolution gas
chromatography (GC) equipped with elec-
tron capture detectors (64,70,74,76–79,
81,84,85,89,90,92). Variations include use of
solid-phase extraction to isolate the lipid frac-
tion (73,75) and the use of high-resolution
gas chromatography–low-resolution mass
spectrometry (87). Other methods include
the use of supercritical CO2 to extract the
lipid, removal of bulk fat using deactivated
alumnia sorbent, and cleanup by adsorption
chromatography followed by GC analysis (71).
The use of U.S. EPA-approved methods has
also been cited by other investigators (80,82). 
The use of QA and QC procedures is
important with any analytic procedure. Several
studies, especially some of the earlier studies,
did not report whether QA or QC procedures
were used (68–70,87). Several investigators
reported participating in regional programs
with interlabortory QA/QC protocols
(78,86,89–91). Other controls included run-
ning analysates in small batches with samples
from cases, controls, reagent blanks and/or QC
pooled samples (64,73,74,76,78,84,89,92),
and/or blinding laboratory personnel to the
nature of the sample (78,88,89). The coefﬁ-
cient of variation in pooled control samples
run with each batch differed widely among dif-
ferent laboratories. Coefﬁcients of variation <
10% were reported by several laboratories
(73,76,88,92), whereas a coefﬁcient of varia-
tion of 21% was reported by Dorgan et al.
(75). The percent recovery of DDE from
spiked samples also varied from laboratory to
laboratory. Zheng et al. (92) reported recover-
ies exceeding 95%; Falck et al. (72) reported
recoveries ranging from 90 to 109%; and
Mussalo-Rauhamaa et al. (91) reported an
80% recovery of an internal standard.
Relative Estrogenic Potencies of DDT
and DDE
The lack of a positive relationship between
levels of DDE in blood or adipose tissue and
breast cancer in many of the published studies
may be caused by the route and magnitude of
exposure to the various congeners of DDT
and metabolites that persist in the environ-
ment and by the differences in their estro-
genicity. The technical DDT that was sprayed
as an insecticide was not a single chemical but
was actually a complex mixture of several
DDT congeners (19). Although the most
estrogenic component of technical DDT has
been consistently identiﬁed as o,p´-DDT, this
form of DDT comprised only about 15–23%
by weight of the technical DDT. About 77%
of the technical DDT was composed of
another congener, p,p´-DDT. Through the
loss of a chlorine, DDT can degrade to DDE,
the most prevalent and persistent metabolite
in the environment (19).
The estrogenic potencies of DDT and its
metabolites have been evaluated in in vivo and
in vitro assays. In in vivo tests of estrogenicity
such as uterine wet weight gain in immature or
ovariectomized rodent uteri, o,p´-DDT has
consistently shown a positive estrogenic
response, whereas p,p´-DDT showed a weaker
response and p,p´-DDE showed little or no
response (43,95). Similarly, o,p´-DDT inhibits
the binding of estradiol to rodent uterine or
recombinant human ER; a less potent response
has been observed for p,p´-DDT, whereas
p,p´-DDE has displayed weak or no binding to
ER (40,41,43,46,47,96–98). Recently, the
ability of different forms of DDT to competi-
tively bind to recombinant human ER-α and
ER-β was investigated by Kuiper et al. (99).
The binding afﬁnity of o,p´-DDT for ER was
10,000-fold (ER-α) to 5,000-fold lower (ER-
β) than that of estradiol. The other DDT con-
geners tested (p,p´-DDT,  o,p´-DDE,
p,p´-DDE) did not show any appreciable
binding to either form of ER. Technical DDT,
o,p´-DDT, o,p´-DDE, p,p´-DDT, and p,p´-
DDE have all demonstrated some capacity to
induce cell proliferation in an ER-dependent
MCF-7 breast tumor cell line [estrogenicity-
screen (E-SCREEN) test], but the magnitude
of proliferation appears to differ according to
the passage and origin of the cell line and con-
ditions of individual laboratories (40,47,48).
Compared to that of estradiol (relative potency
of 1), the relative estrogenic potencies of o,p´-
DDT and p,p´-DDT in the E-SCREEN test
have ranged from 1 ￿ 10–6 to 5 ￿ 10–8, and
from 1 ￿ 10–7 to 5 ￿ 10–9 for p,p´-DDE
(40,48). Although tests of the estrogenicity of
p,p´-DDE have been negative or weakly estro-
genic, there is strong evidence that it can bind
to the androgen receptor, induce androgen
receptor transcriptional activity, and act as an
antiandrogen (97,100,101).
Humans and animals appear to metabolize
technical DDT differently. Some animals and
fish can rapidly metabolize DDT to p,p´-
DDE, and humans can consume preformed
p,p´-DDE from dietary sources and store it in
their adipose tissue. However, studies in male
volunteers fed technical DDT showed little
capacity for humans to metabolize DDT to
DDE (102). The authors suggested that most
of the p,p´-DDE stored in the adipose tissue
in humans is from ingestion of preformed
dietary p,p´-DDE rather than from the con-
version of DDT to p,p´-DDE in their bodies.
This was supported by experiments where
subjects were fed p,p´-DDE directly, and it
was efﬁciently absorbed, stored, and excreted
from the body very slowly (102). Others have
reported a slow conversion of DDT to DDE
in men ingesting DDT (103).
History of Exposure to DDT and DDE
Although p,p´-DDE is used as a surrogate of
past exposure to all sources of DDT and
DDE, there is no way to distinguish how
much of a woman’s exposure was a result of
direct exposure to the technical DDT
sprayed, and hence to the more estrogenic
forms of DDT (o,p´-DDT and p,p´-DDT),
versus how much exposure was due to inges-
tion of dietary preformed p,p´-DDE, which
has little to no evidence of estrogenicity.
Although there is some deposition of DDT
onto American and Canadian soils via
volatilization and atmospheric transport from
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countries in Central and South America that
still use DDT, the magnitude of exposure
through this route is considered to be small
(66). Because of widespread past use of DDT
and the persistence and slow degradation of
its metabolite DDE, low levels of p,p´-DDE
residues are still detected frequently in foods
consumed by Americans, especially in animal
and dairy products, ﬁsh, root vegetables, and
legumes (20,25,26,35,55,58,104). In the
U.S. Food and Drug Administration (FDA)
market-basket surveys conducted from 1991
to 1997, p,p´-DDT and o,p´-DDT were
detected far less frequently than residues of
p,p´-DDE (55). 
Part of the explanation for why most
North American and European studies have
failed to ﬁnd an association between blood or
adipose tissue levels of DDE and breast
cancer risk may be that since the 1970s the
major route of exposure to DDT has not
been through the more estrogenic o,p´-DDT
found in technical DDT that was sprayed as
an insecticide but through the far less estro-
genic p,p´-DDE via the diet. Although use of
DDT in the United States was banned in
1972, DDT production peaked much earlier,
in 1963 at 81 million kg/yr; about 36 million
kg/yr was used in the United States and the
rest was exported. By 1968, use of DDT in
the United States had declined to approxi-
mately 15 million kg/yr (13). The only epi-
demiologic study that collected serum
samples from women when DDT was still
being used heavily in the United States was
conducted by Krieger et al. (63). Samples
were collected from 1964 to 1971. This study
did not find a strong positive association
between DDE levels in serum and breast
cancer risk (Table 1). 
Unfortunately, despite the extensive use
of DDT in agriculture, especially on cotton
crops in the late 1960s, none of the American
epidemiologic studies have evaluated breast
cancer risk in rural farm women potentially
exposed to DDT while it was being used to
treat crops. Other investigators have con-
ducted studies in countries where DDT has
been used more recently and hence there is a
greater potential for women to be exposed to
technical DDT. A small pilot case–control
study compared the serum levels of p,p´-
DDT and p,p´-DDE in 21 women with
breast cancer to 21 controls with BBD from
North Vietnam (79). The primary use of
DDT in Vietnam is for mosquito control.
There was no increase in the relative risk of
breast cancer with higher levels of serum
DDE or DDT in this study, even after
adjustment for age at menarche, parity,
history of lactation, and body weight (DDE
OR 1.14, 95% CI 0.23–5.68; DDT OR
1.21, 95% CI 0.15–9.65; highest tercile com-
pared to lowest tercile). This study did
observe a 3-fold higher level of serum DDT
and DDE in urban populations compared to
rural residents. The authors suggested that
urban residents who could afford to buy
potentially contaminated animal products
may be ingesting more DDT/DDE than are
less economically advantaged rural farmers
who produce the food.
Although the use of DDT in Mexico has
declined from 8,000 tons in 1971 to 2,000
tons in 1994, DDT is still used to control
mosquitoes. A case–control study was con-
ducted to compare serum DDE and DDT
levels in 141 women with breast cancer to
141 noncancer hospital controls from Mexico
City (80). Mean serum DDE levels were
slightly, but not signiﬁcantly, higher in cases
[562.5 parts per billion (ppb), lipid adjusted]
compared to controls (505.5 ppb, p = 0.44),
and the age-adjusted OR for breast cancer
was not different when the lowest tercile for
serum DDE was compared with the highest
tercile (OR 0.97, 95% CI 0.55–1.70). The
OR was lowered even further when adjusted
for BMI, breast feeding, parity, family history
of breast cancer, and time elapsed since last
birth (OR 0.76, 95% CI 0.41–1.42). Relative
risks were not calculated for serum levels of
DDT. Unlike those of p,p´-DDE, the mean
serum levels of p,p´-DDT were lower in cases
(61.45 ppb) than in controls (84.53 ppb), but
this effect was not signiﬁcant (p = 0.26). Even
though DDT is still used in Mexico for vec-
tor control, the valley where the subjects
resided was not an area sprayed for mosqui-
toes. It is possible that the route of exposure
to DDT in urban areas such as Mexico City
may be primarily through DDE in the diet,
and may not be appreciably different from
exposure patterns in other Western countries. 
In contrast, a more recent study conducted
in Mexico City found significantly higher
serum levels of p,p´-DDE in women with
breast cancer than in women without breast
cancer (90). In this study of 120 breast cancer
cases and 126 age-matched community con-
trols, mean serum p,p´-DDE levels (cases
3.84 µg/g lipid, controls 2.51 µg/g lipid) but
not serum p,p´-DDT levels (cases 0.15 µg/g
lipid, controls 0.23 µg/g lipid) were signifi-
cantly elevated (p < 0.05) in women with
breast cancer compared to women without
the disease. The reason for the different
results in these two studies with subjects from
Mexico City is not clear. Romieu et al. (90)
in their discussion, mention that the magni-
tudes of the serum DDE levels are much
higher in their study compared to the values
reported by Lopez-Carrillo et al. (80). If the
serum DDE values are converted to the same
units, then the mean serum DDE levels per
gram lipid are about 7-fold higher in cases
(3.84 µg/g vs. 0.56 µg/g) and 5-fold higher in
controls (2.52 µg/g vs. 0.51 µg/g) in the
Romieu et al. study compared to the Lopez-
Carrillo study, respectively. However, why
the magnitude of the serum DDE levels
would be so different in a population
recruited from the same metropolitan area is
not apparent. The study populations did have
different characteristics. All the subjects in the
Romieu et al. study were parous (at least one
pregnancy), whereas nulliparity was associ-
ated with a higher breast cancer risk among
cases in the Lopez-Carrillo et al. study.
However, one would expect that subjects who
were not parous and therefore had not lac-
tated would have a higher body burden of
DDE. Another possible explanation would be
differences in the analytic methods or
QA/QC procedures between the two labora-
tories. Both studies appear to have used
appropriate methods to analyze the samples.
Lopez-Carrillo et al. (80) used a U.S. EPA-
approved method to analyze samples, but
details on the QA and QC procedures used
were not provided. Romieu et al. (90) used a
standard solvent extraction, Florisil puriﬁca-
tion, and gas chromatography with electron
capture detection procedure. QC procedures
included running internal controls with each
batch of samples, and accuracy was verified
by interlaboratory comparisons. 
No relationship between DDE levels and
breast cancer risk was observed in a Brazilian
case–control study of 177 breast cancer cases
and 350 community controls recruited from
female visitors at the hospital (OR 0.83, 95%
CI 0.40–1.6, p trend = 0.79; comparing high-
est to lowest quintile, OR adjusted for age,
education, parity, lactation, tobacco smoking,
family history of breast cancer, and breast
size) (83). The authors noted that
organochlorine pesticides were used in Brazil
for agriculture until the 1980s and for vector
control programs until the 1990s. This was
one of the few studies that attempted to
obtain information on occupational and
household use of pesticides, including time
lived in a rural area, time lived in a rural area
with pesticide use, time lived in an area with
a vector control program, and occupational
exposure. No relationship was observed
between these types of potential exposures
and differences in breast cancer risk between
cases and controls.
Serum levels of DDE in 153 breast cancer
cases and 153 age-matched controls who were
noncancer hospital patients were compared in
a case–control study conducted in Colombia,
South America (82). The relative risk of
breast cancer was approximately 2-fold higher
in women in the highest tercile compared to
those in the lowest tercile (OR 1.95, 95% CI
1.10–3.52; OR adjusted for breastfeeding
first child, familial history of breast cancer,
parity, BMI, and menopausal status),
although test for trend indicated borderline
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statistical signiﬁcance (p trend = 0.09). DDT
was used until 1986 in Colombian agricul-
ture primarily for cotton, rice, and flower
production and until 1994 for vector control.
One explanation given for the differences
between the positive relationship between
serum DDE and breast cancer risk in this
study (82) versus the lack of relationship in
Lopez-Carrillo et al.’s (80) Mexican study was
differences in the diet between Mexico and
Colombia. Olaya-Contreras et al. (82) cited a
great availability of a variety of fruits, vegeta-
bles, seeds, and grains in Mexico compared to
urban areas of Colombia. No actual dietary
data were collected or reported in either
study, so there are no data to support this
hypothesis.
One shortcoming of most of the studies
that evaluated the relationship between
DDT, DDE, and breast cancer risk is the lack
of extensive exposure histories. Seldom have
the studies attempted to determine whether
the individuals enrolled in the study lived in
areas sprayed with DDT, nor have dietary
histories been taken to estimate possible food-
borne exposures. Although serum or tissue
levels of DDE serve as biomarkers of past
exposure to all forms of DDT, it would
strengthen studies to also gather information
on potential past routes of exposure.
Although recall bias is a common problem in
such surveys, especially among cancer
patients, exposure histories might help inter-
pret study results. The number of published
studies conducted in countries currently
using DDT is relatively low, and none could
be located from countries where there is still
very heavy DDT spraying, such as India. If
the most estrogenic component of technical
DDT—o,p´-DDT—has the potential to act
as an environmental estrogen and to promote
the growth of estrogen-dependent tumors,
women in countries with long and current
histories of DDT use would be the most
important to study if we are to understand
the relationship between DDT and breast
cancer risk. Another potential population to
monitor would be women in the U.S. armed
forces or female spouses of military personnel
who have been stationed in countries that
have actively used DDT during their terms of
service. 
Dietary Factors
Few studies evaluating breast cancer risk and
organochlorine levels have collected dietary
data on their subjects. Moysich et al. (78)
found no differences in postmenopausal breast
cancer patients and community controls with
regard to their fruit, vegetable, dairy, ﬁsh, or
meat consumption. One exception was found
when women were characterized as those who
had ever and those who had never lactated.
Vegetable consumption was significantly
higher in ever-lactating controls compared to
breast cancer cases, though no dietary differ-
ences were observed between cases and con-
trols in the never-lactated group. There were
no significant associations between serum
DDE and breast cancer risk in this study.
Demers et al. (81), in a case–control study
conducted in New Haven, Connecticut, did
ﬁnd that control subjects tended to have diets
with lower fat intakes than did breast cancer
cases, and fat intake was one of the con-
founders used to adjust the relative risks in
this study. However, they found no relation-
ship between serum DDE levels and breast
cancer risk. Aronson et al. (89), in a case–
control study of Canadian women, also
reported a higher intake of dietary fat in cases
than in hospital controls with BBD. Dietary
fat was one of the covariates included in the
confounder model, and although breast cancer
risk was moderately elevated in women with
the highest breast adipose DDE levels (OR
1.62, 95% CI 0.84–3.11), this effect was not
statistically signiﬁcant.
Relationship of DDE to Menopausal
Status and Breast Cancer Risk
Several studies have calculated relative risks of
breast cancer in relation to tissue levels of
DDE after stratifying their sample by
menopausal status. In the study of Canadian
women by Aronson et al., the relative risk of
breast cancer was moderately, though not sig-
nificantly, higher in premenopausal women
with the highest levels of breast adipose tissue
DDE (OR 1.52, 95% CI 0.7–3.33). In con-
trast, there was no association in the post-
menopausal women (OR 1.05, 95% CI
0.5–3.33) (89). A Colombian study also
reported relative risks stratified by
menopausal status. The relative risk was
higher in premenopausal women (OR 2.46,
95% CI 0.96–6.30) than in postmenopausal
women (OR 1.85, 95%, CI 0.85–4.05),
although both groups had elevated relative
risks that were not statistically significant
(82). This is in contrast to the cohort study of
Helzlsouer et al. (73), which evaluated breast
cancer risk in relation to serum DDE levels in
two cohorts: one that donated blood in 1974
and one that donated blood in 1989. They
did not identify any pattern in regard to
menopausal status and breast cancer risk in
women with elevated lipid-adjusted serum
DDE levels compared by tercile. Relative risk
was decreased in both postmenopausal (OR
0.52) and premenopausal women (OR 0.86)
in the 1974 cohort, whereas the relative risk
was elevated in premenopausal women (OR
1.42) but remained below 1 in the post-
menopausal women (OR 0.50) in the 1989
cohort. A small case–control study of only
premenopausal Vietnamese women found no
association between serum DDE levels and
breast cancer risk (OR 1.23, 95% CI
0.23–5.68), and serum DDE levels were not
associated with an increased risk of breast
cancer in a case–control study of post-
menopausal women from western New York
(78). Lopez-Carrillo et al. (80), in a case–
control study of women from Mexico City,
did not observe elevated breast cancer risk
associated with serum DDE levels in pre-
menopausal women (OR 0.64, 95% CI
0.22–1.90) or in postmenopausal women
(OR 0.79, 95% CI 0.27–2.28). In contrast,
Romieu et al. (90) reported a signiﬁcant asso-
ciation between elevated serum DDE levels
and risk of breast cancer in postmenopausal
women from Mexico City (OR 5.26, 95% CI
0.80–34.30, p trend = 0.03; OR adjusted for
age, age at menarche, duration of lactation,
BMI, and serum DDE levels adjusted for
lipid). Breast cancer risk was not associated
with serum DDE levels in the premenopausal
women in this study (90) (OR 2.41, 95% CI
0.37–15.81, p trend = 0.16). There does not
appear to be a consistent pattern of breast
cancer risk related to body levels of DDE and
menopausal status.
Different Types of Control Populations
A potential confounding factor in many of
the case–control studies investigating serum
or adipose tissue organochlorine pesticides
levels and breast cancer risk is the use of con-
trols with BBD. There is some evidence that
women with a previous history of BBD have
a higher risk of breast cancer (76,105). Of the
larger, well-controlled case–control studies,
six recruited controls with BBD (79,84,86,
87,89,92). Except for the study by Güttes et
al. (86), none found a significant positive
relationship between levels of DDE and
breast cancer risk. (I previously discussed the
limitations of the study by Güttes et al.). 
The results of most of the case–control
studies that used other types of control popula-
tions also did not support the hypothesis that
high tissue or blood levels of DDE are posi-
tively related to breast cancer risk. This
includes the study by Lopez-Carrillo et al. (80)
that used noncancer hospitalized controls, the
case–control study conducted by Demers et al.
(81) that used hospitalized noncancer surgical
controls, and the European study conducted
by van’t Veer (88) that used a combination of
population and hospital-based controls (under-
lying condition not speciﬁed). However, all of
these studies used at least some controls that
had underlying medical conditions. One
case–control study that reported a signiﬁcantly
higher level of blood DDE in breast cancer
patients compared to controls did use non-
cancer hospital-based controls and was con-
ducted in Colombia, a country that has a
history of recent use of DDT in agriculture
and vector control (82).
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Four case–control studies (78,83,85,90)
used community/population-based controls,
and three of the studies (73,78,80) did not
report an association between DDE and
breast cancer. This includes a Brazilian
case–control study that compared serum
DDE levels of 151 breast cancer patients with
those of 306 community controls recruited
from hospital visitors. Mendonca et al. (83)
did not observe a significant difference
between serum DDE levels in controls (4.8
ng/mL) compared to those in women with
breast cancer (3.1 ng/mL, p = 0.93). A
case–control study conducted in Italy com-
pared serum DDE levels in 170 breast cancer
cases to those in 190 community controls
(85). The community controls were healthy
women participating in a study on diet and
cancer. Serum p,p´-DDE levels were similar
in cases (9.55 ± 5.42 ng/mL) and controls
(8.98 ± 5.17 ng/mL), and relative risks were
not signiﬁcantly elevated when the highest to
the lowest terciles were compared, even when
adjusted for age, BMI, lactation, parity, and
serum lipids (OR 1.24, 95% CI 0.70–2.20). 
One study that recruited controls from
the community was conducted by Moysich
et al. (78). This study of western New York
women included 154 postmenopausal
women with histologically confirmed breast
cancer and 192 postmenopausal community
controls recruited using names from Health
Care Finance Administration and New York
State Department of Motor Vehicle records.
Mean levels of serum DDE adjusted for age
and serum lipids were similar in cases (11.47
± 10.49 ng/g) and controls (10.77 ± 10.64
ng/g). Although the risk of breast cancer was
moderately elevated in women in the highest
tercile compared to the lowest tercile for
serum DDE, this effect was not statistically
signiﬁcant (OR 1.34, 95% CI 0.71–2.55, p =
0.25; OR adjusted for age, education, family
history of breast cancer, parity, BMI index,
duration of lactation, age at ﬁrst birth, years
since last pregnancy, fruit and vegetable
intake, and serum lipids). The only study
using community controls that did ﬁnd a sig-
nificant positive relationship between serum
DDE levels and breast cancer risk was con-
ducted by Romieu et al. (90), and included
120 breast cancer cases and 126 community
controls from Mexico City. Cases were
recruited from six major hospitals, whereas
controls were randomly selected from the
Mexico City metropolitan area using the
National Household Sampling Frame. The
mean levels of serum p,p´-DDE were signiﬁ-
cantly higher in breast cancer cases (3.84 µg/g
lipid, p < 0.05 by t-test) than in controls
(2.51 µg/g lipid). 
There do not appear to be differences in
the relationship between tissue DDE levels
and breast cancer risk regardless of the type of
control population used. Most of the studies
using either BBD controls, hospital controls,
or community controls did not find a rela-
tionship between levels of DDE or DDT and
breast cancer risk.
Lactation History
The study of western New York women by
Moysich et al. (78) is the ﬁrst to stratify cases
and controls by lactation history, classifying
them as women who have never and ever lac-
tated (Table 1). Because DDT and DDE are
stored in breast fat, it has been hypothesized
(78) that the body burden of lipophilic
organochlorine compounds would be poten-
tially lower in women who have lactated,
because these compounds are excreted in
breast milk. If organochlorine pesticides in
breast fat increase breast cancer risk by acting
as weak estrogens or by other mechanisms, it
could be hypothesized that lowering the body
burden through lactation would reduce breast
cancer risk. As previously mentioned, in the
total population, there was no signiﬁcant dif-
ference in the risk of breast cancer in women
with higher serum DDE levels compared to
women with lower serum DDE levels
(Table 1) (78). When comparing the highest
to the lowest terciles, the risk of breast cancer
was higher, but not significantly higher, for
those who had never lactated (OR 1.83, 95%
CI 0.63-5.33, p = 0.24), whereas there was no
association between serum DDE levels and
breast cancer risk among those who had ever
lactated (OR 1.28, 95% CI 0.54–3.05, p =
0.44). Aronson et al. (89) also stratiﬁed their
sample by lactation history but found an asso-
ciation between lactation and breast cancer risk
only for another organochlorine, Mirex, and
not for adipose DDE. Several case–control and
cohort studies did consider lactation history as
a potential confounder (64,73,76,77,81–84,
90,92). Of the studies that controlled for lacta-
tion in their covariate model, the two studies
that found an association between breast
cancer risk and DDE levels were the 1993
study conducted by Wolff and colleagues (64)
and the study of women from Mexico City
conducted by Romieu et al. (90).
Estrogen Receptor Status
Researchers have also investigated whether
ER status of breast tumors is related to body
burdens of DDT or DDE. Dewailly et al.
(70) compared the concentrations of DDE in
the breast adipose tissue of 9 women with
ER-positive breast tumors, 9 women with
ER-negative tumors, and 17 controls with
BBD. The mean concentrations of DDE in
breast adipose tissue were substantially higher
in the women with ER-positive breast tumors
(2,132.2 ± 2,049 µg/kg) compared with levels
in women with ER-negative breast tumors
(608 ± 338.9 µg/kg) or controls (765.3 ±
526.9 µg/kg). Other case–control and nested
case–control studies did not find a relation-
ship between ER-positive status and levels of
DDE in blood (64,73,76,84) or adipose tis-
sue (87,88). For example, Zheng et al. (84)
reported very similar mean serum DDE levels
for the 163 cases with ER-positive tumors
(435.5 ppb) and the 140 cases with ER-nega-
tive tumors (453.9 ppb). In a study con-
ducted by Wolff and colleagues (64), the
geometric mean serum DDE levels were not
higher, but were lower in cases with ER-
positive tumors (950 ± 2.41 ng/g lipid) com-
pared to cases with ER-negative breast tumors
(1,300 ± 1.79 ng/g lipid). Studies published
to date have not confirmed the observation
originally made by Dewailly et al. (70) of a
relationship between ER-positive receptor sta-
tus of breast tumors and tissue levels of DDE.
Ethnic/Racial Subgroups
Survey studies conducted in the 1970s and
1980s consistently demonstrated that adi-
pose tissue levels of DDE were higher in
American blacks than in whites (28,106),
although whether higher body burdens of
DDE affected the risk of breast cancer was
not evaluated in these studies. In 1994
Krieger et al. (63) published the results of a
nested case–control study of 150 women
with breast cancer; the study examined three
ethnic groups—white, black, and Asian. The
cases and age-matched controls were drawn
from a large cohort of women (57,040) from
the San Francisco Bay area, and blood sam-
ples were obtained in the late 1960s when
DDT was still in use in the United States.
Although the mean levels of DDE in the
serum of the total study population was sim-
ilar in cases (43.3 ± 25.9 ppb) and matched
controls (43.1 ± 23.7 ppb), there were some
differences between DDE levels in cases and
controls among the different ethnic sub-
groups. Mean serum levels of DDE were
higher in black women with breast cancer
(49.2 ± 28.6 ppb) than in controls (43.3 ±
21.2 ppb), whereas among Asian women
DDE levels were higher in controls (50.8 ±
24.7 ppb) than in breast cancer cases (45.1 ±
24.5 ppb). In white women, there was little
difference between mean DDE levels in
cases (35.7 ± 23.0 ppb) and controls (35.0 ±
22.8 ppb), but DDE levels overall were
lower in white women compared to black or
Asian women regardless of cancer status.
These racial/ethnic differences persisted even
after adjustment for age and year of exami-
nation, BMI, educational level, census block
group, working-class composition, poverty
level, place of birth, and pregnancy history.
When multivariate comparisons were made
for the total population, the relative risk
expressed as the adjusted OR for breast
cancer approached significance only for
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black women (OR 3.85, 95% CI 0.93–
16.05, p trend = 0.066; highest total tercile
compared with lowest total tercile for serum
DDE), not for white or Asian women.
However, this association decreased when
black terciles were compared (OR 2.16,
95% CI 0.62–7.58, p trend = 0.208; highest
black tercile compared with lowest black ter-
cile). Krieger et al. (63) concluded that there
was no association between serum DDE lev-
els and breast cancer risk. Others disagree
with this conclusion, contending that the
elevated OR, though not statistically signiﬁ-
cant, does support a positive relationship
between serum DDE levels and breast
cancer risk in black women (107). Krieger
and colleagues’ results are provocative. Of
the five cohort studies published in late
1990s (64,74–77), none had a sufficiently
large number of non-Caucasian women to
address whether there were racial/ethnic dif-
ferences in patterns of breast cancer risk in
relation to organochlorine compounds. 
Several case–control and correlation
studies have attempted to address this issue.
In a case–control study of Connecticut
women, Zheng et al. (92) reported a signiﬁ-
cantly higher average (geometric mean) of
breast adipose tissue DDE levels for black
women (1,926.3 ppb, p < 0.01) than for
white women (917.0 ppb). Although a sepa-
rate multivariate analysis was not conducted
to calculate the relative risks in different eth-
nic subgroups, the OR calculated for the
entire study population was adjusted for con-
founding factors, including race, age, BMI,
lactation history, age at menarche, age at ﬁrst
full-term pregnancy, menopausal status, and
income. There was no association between
levels of breast adipose tissue DDE and breast
cancer risk when the highest quartile was
compared to the lowest quartile (OR 0.9,
95% CI 0.5–1.5, p trend = 0.46). The
authors also noted that the incidence rates for
breast cancer in Connecticut have been
higher in white than in black women for over
20 years (92). This study does not support an
association between higher levels of adipose
DDE and breast cancer risk in black women,
but it does support previous reports of higher
adipose tissue DDE levels in black women
than in white women.
The relationship between adipose DDE
levels and breast cancer mortality recently has
been determined in an ecologic correlation
study that included data from 22 U.S. states
(108). Data on the DDE concentrations in
subcutaneous fat samples were obtained from
a U.S. EPA human monitoring report. No
information was available on how the fat
samples were obtained, stored, or analyzed.
Because this was an ecologic study, no infor-
mation was available on possible confound-
ing factors; the report provided data only on
the average DDE levels and sample size by
state and race. With the exception of New
York State, which had similar adipose DDE
levels among blacks and whites, adipose lev-
els of DDE were higher in blacks in all 18
states that reported data on both blacks and
whites. The three states with the highest adi-
pose DDE levels in blacks were Arkansas,
Texas, and South Dakota. Western and
southern states had higher adipose DDE lev-
els than eastern and midwestern states.
Mortality from cancer of the breast was
inversely correlated with adipose DDE levels
both in whites (r = –0.73, p < 0.01) and in
blacks (r = –0.50, p < 0.05). None of the
other cancer sites studied had positive corre-
lations with adipose tissue DDE levels in
whites or blacks, except for liver cancer,
which was positively correlated in whites and
negatively correlated in blacks. Because the
mortality rate for breast cancer is only about
25%, more meaningful data would have
included an analysis of breast cancer inci-
dence rates. This study does not support a
positive relationship between body burdens
of DDE and breast cancer mortality in black
or white American women; however, these
results must be viewed with caution because
cause-and-effect relationships cannot be
inferred from ecologic studies. 
If there is a relationship between breast
cancer risk and serum organochlorine levels, it
could be hypothesized that those populations
with the highest body burdens of such chemi-
cals would be priority subpopulations to evalu-
ate. Although most case–control and cohort
studies to date do not support an association
between serum DDE levels and breast cancer
risk in white women, few studies have explored
whether women of different racial or ethnic
backgrounds may be subpopulations at risk
because of higher body burdens of organo-
chlorine compounds. More studies are needed
to follow up on the observations of Krieger
et al. (63) that black women with breast cancer
tend to have higher blood levels of DDE than
black women without breast cancer. 
Breast Tumor Characteristics
Although most of the larger, well-controlled
human epidemiologic studies have not sup-
ported a relationship between body burden of
DDE or DDT and breast cancer risk, others
have begun to investigate whether these
organochlorines influence the tumor stage,
size, or metastatic potential of breast tumors.
The age- and lipid-adjusted levels of serum
DDE were compared between controls and
cases according to stage of tumor in a
case–control study by Zheng et al. (84).
There were no signiﬁcant differences between
the geometric means for serum DDE in con-
trols (456.2 ppb) and those in cases with
breast tumors classified as stage 0-II (455.9
ppb, p < 0.99) or stage III-IV (402.1 ppb, p <
0.57). Hunter et al. (76) did not ﬁnd an asso-
ciation between breast cancer risk and serum
DDE levels in a nested case–control study of
236 breast cancer patients and 236 matched
controls from the Nurses’ Health Study
cohort (OR 0.72, 95% CI 0.37-1.40, p trend
= 0.47). There were also no differences in the
levels of DDE in the serum of cases with or
without axial lymph-node involvement [data
mentioned but not shown by Hunter et al.
(76)]. These results suggest that serum DDE
levels are not predictive of the metastatic
potential of breast tumors. 
The results reported by Hunter et al. (76)
are in contrast to those in a Canadian
case–control study of the aggressiveness of
breast tumors in relation to plasma DDE lev-
els reported by Demers et al. (81). Although
there were similar mean levels of plasma
DDE in the 314 cases (508.9 ± 49.1 µg/kg
lipid basis), 218 hospital-based controls
(462.7 ± 447.7 µg/kg), and 305 population
controls (480.4 ± 408.4 µg/kg), there was evi-
dence of a positive relationship between
plasma DDE levels and lymph node involve-
ment in the breast cancer cases. The relative
risk for lymph node involvement was signiﬁ-
cantly elevated in the highest compared to the
lowest quintile for plasma p,p´-DDE (OR
2.54, 95% CI 1.20–5.35; adjusted for age,
region of residence, BMI, time separating
blood sampling from surgery, lactation dura-
tion, number of fertile years, and tumor size).
Statistical signiﬁcance was observed only after
adjusting for confounding factors, not in the
unadjusted data. Tumor size alone was not
associated with plasma DDE levels (OR 1.18,
95% CI 0.56–2.21). Whether tissue levels of
p,p´-DDE influence the stage of breast
cancer, metastatic potential, or lymph node
involvement of breast tumors should be stud-
ied further, as it is impossible to make a con-
clusion based on the few studies conducted
thus far.
Polymorphisms
It is beyond the scope of this review to discuss
the numerous studies devoted to identifying
polymorphisms that may influence steroid
hormone synthesis, degradation, hydroxyla-
tion, and the transformation of chemicals
into potential carcinogens. Polymorphisms in
CYP17, CYP19, CYP1B1, CYP1A1, COMT,
and I1307K have been associated with breast
cancer risk (109–115). Whether polymor-
phisms play a role in breast cancer risk in
relation to tissue organochlorines is a topic of
emerging interest; few studies have been
published to date. Helzlsouer et al. (73)
found no evidence of a relationship between
polymorphisms of GSTM1, GSTT1, GSTP1,
COMT, and CYP17, serum concentrations
of DDE and breast cancer risk in a nested
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case–control study of 346 breast cancer
patients and 346 matched controls. It is
expected that this will be an active area of
future research.
Dieldrin
Recent reports of an association between
blood levels of dieldrin and the risk of breast
cancer in Danish women (74,116) have been
of great interest. Dieldrin is a persistent
organochlorine pesticide that was used in the
United States from the 1950s to the mid
1970s against soil insects to protect agricul-
tural crops. Its use continued as a termiticide
for crack, crevice, and foundation treatment
until it was banned by the U.S. EPA in 1987
(12). Aldrin, a structurally similar organochlo-
rine pesticide with similar uses, can degrade to
dieldrin. All uses of aldrin were banned by the
U.S. EPA in 1987 (12).
Epidemiologic Studies on Dieldrin 
and Breast Cancer Risk
The potential of dieldrin to affect breast cancer
risk was evaluated by Danish researchers in a
prospective nested case–control study that
included 7,712 women enrolled in the
Copenhagen City Heart Study (74). Serum
samples were obtained from participants from
1976 to 1978. In 1996–1997, researchers ana-
lyzed serum samples from 240 women who
had developed invasive breast cancer and 477
matched breast cancer-free controls for levels
of kepone, dieldrin, o,p´-DDT, p,p´-DDT, β-
hexachlorocyclohexane, and several PCB con-
geners. Controls and cases were matched for
age, date of examination, and vital status at
the examination. Information was obtained
on potential confounding factors, including
weight, height, number of full-term pregnan-
cies, alcohol consumption, smoking, physical
activity, menopausal status, household
income, marital status, and education.
Independent of breast cancer status, dieldrin
was detected in 78% of the women enrolled
in the study, with median levels at 24.4 ng/g
lipid. There was no relationship of breast
cancer risk to serum levels of several PCB
congeners, DDE or DDT, or β-hexachloro-
cyclohexane. The only organochlorine com-
pound associated with a signiﬁcant increase in
breast cancer risk was dieldrin. Women in the
highest quartile had double the risk of breast
cancer compared to women in the lowest
quartile (OR 2.25, 95% CI 1.32–3.84, p
trend = 0.003). Relative risks remained
unchanged (OR 2.05, 95% CI 1.17–3.57, p
trend = 0.01) when adjusted for confounding
factors (number of full-term pregnancies and
weight). The strengths of this study include
its prospective design, that blood samples
were obtained before the onset of disease, and
its evaluation of a variety of organochlorine
compounds.
A subsequent study using the same cohort
of Danish women investigated whether breast
cancer survival was affected by past exposure
to dieldrin (116). To test this hypothesis,
researchers obtained serum from 195 women
with breast cancer who provided blood sam-
ples during two collections, 1976–1978 and
1981–1983, and analyzed the samples for lev-
els of dieldrin. The Causes of Death Registry
from the Danish National Board of Health
was the source of information for the causes
and times of death. Those with the highest
blood dieldrin levels from the 1976–1978
blood collection had signiﬁcantly higher risks
of dying than those with the lowest levels [rel-
ative risk (RR) 2.78, 95% CI 1.38–5.59,
p trend < 0.01; highest quartile compared to
lowest quartile]. When the analysis was per-
formed using an average of the blood dieldrin
levels from the two collections, the associa-
tion was even stronger, with a 5-fold higher
risk of dying in women from the highest
compared to the lowest quartile (RR 5.76,
95% 1.86–17.92, p trend < 0.01). In both
analyses, relative risks were adjusted for num-
ber of positive lymph nodes and tumor size
and grade. The authors stated that these ﬁnd-
ings suggest that past exposure to dieldrin
may affect both the risk of developing breast
cancer and survival postdiagnosis.
Few studies have evaluated whether serum
or adipose dieldrin levels can predict breast
cancer risk in American women. Dieldrin was
undetectable in adipose tissue samples
obtained from ﬁve breast cancer cases and ﬁve
hospital controls without breast cancer
enrolled in a study conducted at the Long
Island Jewish Medical Center in New Hyde
Park, New York (71).
A prospective cohort study of women
from Missouri failed to find an association
between serum dieldrin levels and breast
cancer risk (75). Blood samples were donated
by 7,224 women in this cohort from 1977 to
1987. During the 9.5-yr follow-up period,
105 women developed breast cancer; each
was matched to two controls based on age
and date of blood collection. Dieldrin was
detected in serum at levels above the limit of
detection in 56.2% of the cases and in 61.8%
of the controls. The relative risk of breast
cancer in relation to serum dieldrin levels was
moderately lower when the highest quartile
was compared to the lowest quartile (RR 0.6,
95% CI 0.3–1.3, p = 0.38). Because dieldrin
was detected only in a little over half the cases
in this study, it may not prove to be a useful
marker of organochlorine exposure or breast
cancer risk in American women. The only
organochlorine associated with a higher risk
of breast cancer in this study was hexa-
chlorobenzene.
The evidence for an association between
dieldrin and breast cancer risk from human
epidemiologic studies is equivocal, and more
studies must be conducted before any conclu-
sion can be made about the significance of
this association. 
Epidemiologic Studies of Dieldrin and
Other Hormonally Dependent Cancers
There is limited evidence from one other
study that dieldrin exposure may be related to
the risk of other hormonally dependent can-
cers. A small case–control study examined the
relationship between blood levels of a variety
of estrogenic organochlorine pesticides,
including dieldrin, and the risk of endome-
trial cancer (117). Serum samples were
obtained from 90 women with endometrial
cancer and 90 matched community controls
in five geographic locations in the United
States. Trained interviewers obtained infor-
mation on potential confounders, including
reproductive and menstrual history, oral con-
traceptive use, menstrual estrogen use, waist-
to-thigh circumference ratio, total caloric
intake, fat intake, cigarette smoking, and
body weight. Of the organochlorine pesti-
cides or metabolites evaluated (p,p´-DDE,
o,p´-DDT, p,p´-DDT, β-hexachlorocyclo-
hexane, dieldrin, heptachlor epoxide, oxy-
chlordane, trans-nonachlor), the risk of
endometrial cancer was elevated, though not
signiﬁcantly, only for dieldrin. The adjusted
RR for endometrial cancer and serum dield-
rin levels by tercile was 2.1 (95% CI 0.9–4.2)
in the mid-tercile and 1.9 (95% CI 0.7–4.8)
in the highest tercile. Although the results
from this small case–control study need to be
confirmed, they provide some support for a
possible relationship between dieldrin and the
risk of hormonally dependent cancers.
Evidence of the Estrogenicity of Dieldrin
The mechanism by which dieldrin may
increase the risk of breast or uterine cancer has
not been established, although the ability of
dieldrin to act as a xenoestrogen has been
given as a possible explanation (74). However,
closer examination of the studies that have
evaluated the estrogenicity of dieldrin indi-
cate that it is at best a very weak estrogen, and
in other tests its ability to act as an estrogen
could not be demonstrated. 
The most frequently cited evidence for the
estrogenicity of dieldrin is the positive response
documented in the E-SCREEN assay, which
measures cell proliferation in an estrogen-
dependent MCF-7 breast tumor cell line
(48,118). However, dieldrin elicited an estro-
genic response only at the highest concentra-
tion tested (10 µM), with no proliferative
response in MCF-7 cells at lower doses (118).
The relative potency of dieldrin compared to
estradiol was calculated to be 1 ￿ 10–6 from
the E-SCREEN assay (118), and 5 ￿ 10–7
from an ER-mediated luciferase reporter gene
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assay (119). Others have observed minimal
estrogenic responses for dieldrin in MCF-7
proliferative assays or in yeast-based ER assays
(120). In other experiments conducted by Soto
et al. (48), dieldrin was unable to induce prog-
esterone receptor levels but did significantly
induce pS2 levels. Researchers have not been
able to demonstrate an estrogenic uterotropic
response to dieldrin in in vivo tests using
immature rat or mouse uteri (46,121). In ER-
binding assays, the ability of dieldrin to dis-
place tritiated estradiol from ER isolated from
rodent or rabbit uteri or from alligator ER has
been minimal (96,121,122) or tests have
yielded negative results (46,123). However, it
can be argued that the competitive ER-binding
assays may not reflect the capacity of a
lipophilic compound with low aqueous solu-
bility to compete for occupancy on ERs iso-
lated from crude uterine preparations. To
address this problem a new ﬂuorescence polar-
ization (FP) method that measures the ability
of a chemical to displace a high-afﬁnity ﬂuo-
rescent ligand from purified, recombinant
human ER was developed by Bolger et al. (96).
In the FP assay, dieldrin showed little capacity
to inhibit binding of estradiol to purified
human ER. Even at the maximal dieldrin con-
centration tested of 2 ￿ 10–5 µM, estradiol
binding was inhibited less than 25%.
Although there is little evidence of dieldrin’s
estrogenicity, one study has demonstrated that
it may act as an antiandrogen. Dieldrin
induced a 30% inhibition of tritiated 5-α
dehydrotestosterone binding to rat prostate
androgen receptor (46). 
Potential Routes of Exposure to Dieldrin
One study attempted to document occupa-
tional exposure to chemicals in women resid-
ing on Cape Cod, Massachusetts. The
researchers found that of the 261 breast
cancer cases and the 753 controls in the
study, only a small number of subjects (2–33)
had probable or possible occupational expo-
sure to dieldrin or to a variety of other
organochlorines (124).
Some estimates have been made of the
potential of exposure to organochlorines,
including dieldrin, in the American diet. The
U.S. FDA has published data on the residues
of pesticides, including dieldrin, found in
foods analyzed as a part of their market-basket
surveys conducted from 1991 to 1997 (55).
Dieldrin was found in low levels in a variety of
foods, including dairy products, meat and
poultry products, legumes, eggs, root vegeta-
bles such as potatoes, beets, turnips, leafy
greens, and vegetables like squash that can
come in contact with soil when grown.
MacIntosh et al. (58) estimated potential
dietary exposures using food consumption
data collected as a part of the Nurses’ Health
Study and Health Professionals’ Follow-up
Study with food residue data from the FDA
Total Diet Study. Mean estimated dietary
exposures in 1990 for dieldrin were estimated
at 0.5 µg/day for males and females, with
maximum levels at 4.3 µg/day for females and
16.9 µg/day for males. Estimates of adult
intake of dieldrin in the United States or
Denmark compiled from data from the early
1980s estimated the average daily intake of
dieldrin at 0.02 µg/kg body weight (60 kg
female = 1.2 µg/day dieldrin; 80 kg male = 1.6
µg/day dieldrin) (125). This is generally con-
sistent with the observation that dieldrin levels
have been declining in food samples and
human tissues since its ban for agricultural use
in the mid-1970s and its ban for termiticide
use in the late 1980s (62).
Because of its persistence in soil and low
mobility, dieldrin is seldom detected as a
water contaminant in the United States. A
study conducted by the U.S. Geological
Survey from 1993 to 1995 in 20 major
hydrologic basins throughout the United
States reported very low frequencies of
dieldrin in groundwater, regardless of type of
land use (126). Overall, only 1.4% of the
1,034 sites sampled had detectable levels of
dieldrin. The type of land use with the high-
est percent detection was orchards and vine-
yards, with an average of 3.3% of the sites
with detectable levels of dieldrin. Dieldrin has
been detected in areas with past historical use.
In a study of 50 shallow wells from Suffolk
County, New York, which has a sandy and
gravel aquifer susceptible to contamination,
New York State Class GA standards for dield-
rin in groundwater were exceeded in eight
wells (standard is 0.004 µg/L for dieldrin).
The highest dieldrin level detected in a
Suffolk County well was 0.1 µg/L (127).
Conclusions and Needs 
for Further Research
Most of the nested case–control and case–
control studies conducted since 1996 have
failed to confirm earlier observations of a
significant positive relationship between
serum or adipose tissue levels of DDE or
DDT and breast cancer risk. Most of these
studies have been conducted using
Caucasian women from the United States,
Canada, or Europe. Because some studies
have documented a tendency for black
women in the United States to have higher
serum or adipose DDE levels than white
women, further studies are needed to deter-
mine whether black women have a higher
risk for breast cancer associated with body
burdens of DDE. 
One reason for the lack of association
between blood or tissue DDE levels and breast
cancer risk may be the route of exposure to
different forms of DDT and its metabolites of
varying estrogenicity. Speciﬁcally, in Western
populations, the primary contribution to body
levels of DDE may be via p,p´-DDE ingested
preformed from the diet rather than exposure
to technical DDT, which contains the more
estrogenic congener o,p´-DDT. 
Although it does not appear that DDE
predicts breast cancer risk in white Western
women in North America or in Europe, there
are other populations with more recent
exposure to DDT that it may be prudent to
evaluate. Some of the studies conducted in
countries with more recent DDT use have not
found a relationship to breast cancer risk
(79,80,83), but two studies, conducted in
Colombia, South America (82), and in Mexico
City (90), have found an elevated risk of breast
cancer in women with higher serum levels of
DDE. To test whether the estrogenic o,p´-
DDT found in technical DDT is capable of
supporting the growth of estrogen-dependent
breast tumors, further studies should be con-
ducted in Third World countries, such as
India, that have a long and continuing history
of DDT use. 
It is not possible to conclude whether
serum dieldrin levels are associated with breast
cancer risk until the results of other studies
become available. Studies done to date have
found a relationship between serum dieldrin
levels and breast cancer risk in Danish but not
American women. An area of research that
should be pursued is whether body burdens of
DDE or dieldin are associated with tumor
size, metastatic potential, or morbidity from
breast cancer. Other emerging areas of
research will be the relationship to poly-
morphisms and organochlorine levels to breast
cancer risk.
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